




# PHARMACEUTICAL 2022

NeuroBo Pharmaceuticals Inc.  
Rank 259 of 466





## PHARMACEUTICAL 2022

NeuroBo Pharmaceuticals Inc.  
Rank 259 of 466

The relative strengths and weaknesses of NeuroBo Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NeuroBo Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 50% points. The greatest weakness of NeuroBo Pharmaceuticals Inc. is the variable Net Income, reducing the Economic Capital Ratio by 88% points.

The company's Economic Capital Ratio, given in the ranking table, is 103%, being 25% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	16,584
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,157
Liabilities, Non-Current	45
Other Assets	105
Other Compr. Net Income	-10
Other Expenses	0
Other Liabilities	0
Other Net Income	14
Other Revenues	0
Property and Equipment	110
Research and Development	6,546
Selling, General and Administrative Expense	8,752

Output Variable	Value in 1000 USD
Assets	16,799
Liabilities	2,202
Expenses	15,298
Revenues	0
Stockholders Equity	14,597
Net Income	-15,284
Comprehensive Net Income	-15,289
Economic Capital Ratio	103%